Citizens raises Taysha price target to $11, maintains outperform

0 min read Updated on 23 Jun 2026, 07:31 PM

Reviewed by

Radhika SScanX News Team

AI Summary

Citizens analyst Silvan Tuerkcan maintained a Market Outperform rating on Taysha Gene Therapies and increased the price target from $8 to $11.

*this image is generated using AI for illustrative purposes only.

Citizens analyst Silvan Tuerkcan has maintained a Market Outperform rating on Taysha Gene Therapies and raised the price target to $11. The previous target was $8. The company trades on the NASDAQ under the ticker symbol TSHA.

Rating and Target Details

The revised price target reflects an increased valuation outlook for the biotechnology firm. The Market Outperform rating indicates expectations for the stock to perform better than the broader market average.

Metric	Value
Rating	Market Outperform
New Price Target	$11
Previous Price Target	$8

What specific factors drove the 37.5% increase in Taysha's price target?

How might this rating upgrade influence investor sentiment towards Taysha in the short term?

What upcoming clinical milestones could further impact Taysha's stock performance?

Read Next Article

Taysha completes dosing in REVEAL pivotal trial for Rett syndrome

0 min read Updated on 22 Jun 2026, 06:56 PM

Reviewed by

Suketu GScanX News Team

Add as a preferred
source on Google

AI Summary

Taysha Gene Therapies completed dosing in the REVEAL pivotal trial for Rett syndrome and reported positive data from Phase 1/2 trials, marking progress in its AAV-based gene therapy TSHA-102.

*this image is generated using AI for illustrative purposes only.

Taysha Gene Therapies, Inc. has completed dosing in the REVEAL pivotal trial evaluating TSHA-102 for the treatment of Rett syndrome. The company also reported positive longer-term clinical data from Part A of the REVEAL Phase 1/2 trials. TSHA-102 is an adeno-associated virus (AAV)-based gene therapy designed for severe monogenic diseases of the central nervous system (CNS).

Trial Details

The REVEAL pivotal trial focuses on the developmental plateau population of Rett syndrome. The completion of dosing marks a significant milestone in the clinical development of TSHA-102. The positive data from Part A of the Phase 1/2 trials supports the continued advancement of the therapy.

About TSHA-102

TSHA-102 is being developed as a potential treatment for Rett syndrome, a severe genetic neurological disorder. The therapy utilizes AAV-based gene therapy to target the underlying cause of the disease. The reported longer-term clinical data from the Phase 1/2 trials indicates promising results for patients.

What are the anticipated timelines for releasing top-line data from the REVEAL pivotal trial?

How might the positive Phase 1/2 data influence regulatory discussions and potential approval pathways?

What strategies could Taysha employ to scale manufacturing if TSHA-102 receives market approval?